Viking Therapeutics: What's Happening With VKTX Stock?

Viking Therapeutics (VKTX) shares dropped 42% after its oral obesity drug VK2735’s Phase 2 results showed a weaker 12.2% weight loss and a 28% patient discontinuation rate, underperforming competitor therapies. Despite the significant selloff, the article suggests the decline is overdone given Viking's diversified pipeline, which includes a promising subcutaneous VK2735 formulation in Phase 3 trials and VK2809 for NASH/MASH, among other assets. Trading at a steep discount to analyst targets, VKTX presents a speculative opportunity for risk-tolerant, long-term investors, as its broad pipeline may offer significant upside despite the setback of a single program.

Analysis

Viking Therapeutics (VKTX) experienced a significant 42% share price decline after its oral obesity drug, VK2735, delivered disappointing Phase 2 results. The trial data showed a weight loss of up to 12.2% and a high patient discontinuation rate of 28% due to side effects, a weaker profile compared to late-stage treatments from competitors Eli Lilly and Novo Nordisk. Despite this setback, the market reaction appears disproportionate given Viking's status as a pre-commercial entity with a diversified clinical pipeline. The company's value is not solely tied to the oral formulation; its subcutaneous version of VK2735, which previously demonstrated a more promising 13.1% placebo-adjusted weight loss, is advancing into Phase 3 trials. Furthermore, Viking possesses other key assets, including VK2809 for NASH/MASH, which has successfully completed its Phase 2b trial, and several other earlier-stage candidates. The resulting valuation, with the stock at $24 against an $89 average analyst price target, suggests a potential dislocation, as the sell-off heavily discounts the prospects of the company's broader portfolio for the failure of a single program.

Key Decisions for Investors

• For risk-tolerant, long-term investors, the current valuation may represent a speculative entry point, as the market appears to have overly punished the stock for one program's setback while undervaluing a diversified pipeline.
• Investors should closely monitor upcoming catalysts that could re-rate the stock, particularly progress updates from the Phase 3 VANQUISH trials for the subcutaneous VK2735 and developmental milestones for the NASH/MASH candidate, VK2809.
• It is crucial to weigh the opportunity against significant risks, including the substantial capital required to fund multiple Phase 3 trials, intense competition in metabolic disorders, and the potential for additional clinical disappointments.